Search

Your search keyword '"MacCarrone M"' showing total 1,388 results
Start Over Author "MacCarrone M"
1,388 results on '"MacCarrone M"'

1. Contributors

Author

Askari, Vahid Reza, primary, Aso, Ester, additional, Baradaran Rahimi, Vafa, additional, Baraibar, Andrés M., additional, Barnes, Robert, additional, Battini, Renata, additional, Bernal-Chico, Ana, additional, Bertoglio, Leandro José, additional, Best, Laura M., additional, Binda, Karina Henrique, additional, Boccella, Serena, additional, Boileau, Isabelle, additional, Bolkent, Sema, additional, Castro-Piedras, Isabel, additional, Chacur, Marucia, additional, Ciruela, Francisco, additional, Colomer, Teresa, additional, Corrêa, Moisés Dos Santos, additional, Correia-Sá, Inês, additional, Criscuolo, E., additional, Crombie, Kevin M., additional, Crosby, Karen M., additional, Cysneiros, Roberta Monterazzo, additional, da Silva, Ana P. dos Santos C. L, additional, da Silva, Bruna Vougado, additional, da Silva Lopes, Luciano, additional, da Silva Oliveira, George Laylson, additional, De Sciscio, M.L., additional, del Torrent, Claudia Llinás, additional, Diester, Clare M., additional, Dvorakova, Michaela, additional, Evans, José Fuentealba, additional, Faúndez Parraguez, Manuel, additional, Fezza, F., additional, Fornari, Raquel Vecchio, additional, Franco, Rafael, additional, Fu, Rao, additional, Fusco, Antimo, additional, Ganguly, Dipyaman, additional, Gazarini, Lucas, additional, Ghazali, Reem, additional, Glass, Michelle, additional, Gordon, Rita, additional, Gu, Xinyu, additional, Guindon, Josée, additional, Gyamfi, Daniel, additional, Heinbockel, Thomas, additional, Hellman, Judith, additional, Infantino, Rosmara, additional, Kabir, Morvarid, additional, Kandasamy, Ram, additional, Kassiou, Michael, additional, Kalinovsky, Anna, additional, Kitchigina, Valentina, additional, Koyama, Sachiko, additional, Leo, Eliana, additional, Liang, Jian, additional, Lillo, Jaume, additional, Lin, Yu-Fung, additional, Lloyd, Elliot, additional, Lu, Dai, additional, Maccarrone, M., additional, Mahabadi, Hajar Miranzadeh, additional, Maione, Sabatino, additional, Maldonado-Vlaar, Carmen S., additional, Manucha, Walter, additional, Maretti, Eleonora, additional, Martín Giménez, Virna M., additional, Martínez-Aguirre, Christopher, additional, Mato, Susana, additional, Matute, Carlos, additional, Mayo, Leah M., additional, McCormick, Cheryl M., additional, McHann, Melissa, additional, Mikheeva, Irina, additional, Molinari, Susanna, additional, Moreno-Garcia, Álvaro, additional, Navarro, Gemma, additional, Negus, S. Stevens, additional, Ney, Luke J., additional, Nguyen, Nina, additional, Niemela, Greta, additional, Norzé, Wickensonn, additional, Nuñez-Lumbreras, María de los Ángeles, additional, Palazzo, Enza, additional, Pan, Ying-Xian, additional, Patel, Vinood B., additional, Pecic, Stevan, additional, Perez-Valenzuela, Enzo, additional, Perrone, Michela, additional, Poluga, Claudia, additional, Poole, Emily I., additional, Preedy, Victor R., additional, Raïch, Iu, additional, Rajendram, Rajkumar, additional, Raymundi, Ana Maria, additional, Real, Caroline C, additional, Reekie, Tristan A., additional, Reyes-Resina, Irene, additional, Ribeiro, Fernanda Teixeira, additional, Rivas-Santisteban, Rafael, additional, Rocha, Luisa, additional, Sánchez, Ester, additional, Simone, Jonathan J., additional, Stern, Cristina Aparecida Jark, additional, Taghibiglou, Changiz, additional, Tam, Kelsey, additional, Tanaka, Mikiei, additional, Terry, Garth E., additional, Utrilla, Carmen L., additional, Varlow, Cassis, additional, Vasdev, Neil, additional, Wierenga, Corette J., additional, Woodward, John J., additional, Yazici, Zeynep Mine Coskun, additional, Ye, Jiang-Hong, additional, Zhang, Yumin, additional, and Zuo, Wanhong, additional

Published
2023
Full Text
View/download PDF

3. The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease

Author

Di Sabatino, A, Battista, N, Biancheri, P, Rapino, C, Rovedatti, L, Astarita, G, Vanoli, A, Dainese, E, Guerci, M, Piomelli, D, Pender, SLF, MacDonald, TT, Maccarrone, M, and Corazza, GR

Subjects
Digestive Diseases, Autoimmune Disease, Crohn's Disease, Cannabinoid Research, Inflammatory Bowel Disease, Oral and gastrointestinal, Animals, Arachidonic Acids, Cannabinoid Receptor Modulators, Cytokines, Humans, Inflammatory Bowel Diseases, Intestinal Mucosa, Intestines, Mice, Myofibroblasts, Receptor, Cannabinoid, CB1, Receptor, Cannabinoid, CB2, STAT4 Transcription Factor, T-Box Domain Proteins, Biological Sciences, Medical and Health Sciences, Immunology
Abstract

Activation of cannabinoid receptors (CBs) by endocannabinoids impacts on a number of gastrointestinal functions. Recent data indicate that CB1 agonists improve 2,4-dinitrobenzene sulfonic acid-induced colitis in mice, thus suggesting a role for the endocannabinoid agonist anandamide (AEA) in protecting the gut against inflammation. We here examined the gut endocannabinoid system in inflammatory bowel disease (IBD) patients, and investigated the ex vivo and in vitro effects of the non-hydrolysable AEA analog methanandamide (MAEA) on the mucosal proinflammatory response. The content of AEA, but not of 2-arachidonoyl-glycerol and N-palmitoylethanolamine, was significantly lower in inflamed than uninflamed IBD mucosa, and this was paralleled by lower activity of the AEA-synthesizing enzyme N-acyl-phosphatidylethanolamine-specific phospholipase D and higher activity of the AEA-degrading enzyme fatty acid amide hydrolase. MAEA significantly downregulated interferon-γ and tumor necrosis factor-α secretion by both organ culture biopsies and lamina propria mononuclear cells. Although these results are promising, further studies are needed to determine the role of cannabinoid pathways in gut inflammation.

Published
2011

8. Cellular assay to study β-arrestin recruitment by the cannabinoid receptors 1 and 2

Author

Bouma, J., Soethoudt, M., Gils, N. van, Xia, L., Stelt, M, van der, Heitman, L.H., Maccarrone, M., Maccarrone, M., and Hematology laboratory

Abstract

Cannabinoid receptor 1 (CB1R) and cannabinoid receptor 2 (CB2R) are G protein-coupled receptors (GPCRs) that activate a variety of pathways upon activation by (partial) agonists including the G protein pathway and the recruitment of β-arrestins. Differences in the activation level of these pathways lead to biased signaling. Here, we describe a detailed protocol to characterize the potency and efficacy of ligands to induce or inhibit β-arrestin recruitment to the human CB1R and CB2R using the PathHunter® assay. This is a cellular assay that uses a β-galactosidase complementation system which has a chemiluminescent read-out and can be performed in 384-well plates. We have successfully used this assay to characterize a set of reference ligands (both agonists, antagonists, and an inverse agonist) on human CB1R and CB2R, of which some examples will be presented here.

Published
2022
Full Text
View/download PDF

10. POS0237 ADULT-ONSET STILL’S DISEASE AND COVID 19 SHARE GENETIC EXPRESSION RELATED TO HYPERINFLAMMATION: DEFINING THE POSSIBLE ROLE OF THE SPECIALIZED PRO-RESOLVING LIPID MEDIATOR PROTECTIN D1 IN MODULATING MACROPHAGES POLARIZATION AND FUNCTION

Author

Navarini, L., primary, Vomero, M., additional, Currado, D., additional, Berardicurti, O., additional, Biaggi, A., additional, Marino, A., additional, Bearzi, P., additional, Corberi, E., additional, Rigon, A., additional, Arcarese, L., additional, Leuti, A., additional, Fava, M., additional, Fogolari, M., additional, Mattei, A., additional, Ruscitti, P., additional, DI Cola, I., additional, Sambuco, F., additional, Travaglino, F., additional, Angeletti, S., additional, Ursini, F., additional, Mariani, E., additional, Agrò, F. E., additional, Cipriani, P., additional, Iagnocco, A., additional, Antonelli Incalzi, R., additional, Maccarrone, M., additional, and Giacomelli, R., additional

Published
2023
Full Text
View/download PDF

16. Oxygenation of anandamide by lipoxygenases

Author

Zadelhoff, G. van, Stelt, M. van der, and Maccarrone, M.

Subjects
0301 basic medicine, biology, 2-Arachidonoylglycerol, Anandamide, Endocannabinoid system, Serine, Monoacylglycerol lipase, 03 medical and health sciences, chemistry.chemical_compound, Lipoxygenase, 030104 developmental biology, 0302 clinical medicine, chemistry, Biochemistry, Fatty acid amide hydrolase, biology.protein, lipids (amino acids, peptides, and proteins), Arachidonic acid, 030217 neurology & neurosurgery
Abstract

The endocannabinoids anandamide and 2-arachidonoylglycerol are not only metabolized by serine hydrolases, such as fatty acid amide hydrolase, monoacylglycerol lipase, and α,β-hydrolases 6 and 12, but they also serve as substrates for cyclooxygenases and lipoxygenases. These enzymes oxygenate the 1Z,4Z-pentadiene system of the arachidonic acid backbone of endocannabinoids, thereby giving rise to an entirely new array of bioactive lipids. Hereby, a protocol is provided for the enzymatic synthesis, purification, and characterization of various oxygenated metabolites of anandamide generated by lipoxygenases, which enables the biological study and detection of these metabolites.

Published
2022

25. Chemical Proteomics Reveals Off-Targets of the Anandamide Reuptake Inhibitor WOBE437

Author

Gagestein, B., Stevens, A.F., Fazio, D., Florea, B.I., Wel, T. van der, Bakker, A.T., Fezza, F., Dulk, J. den, Overkleeft, H.S., Maccarrone, M., and Stelt, M. van der

Subjects
Proteomics, Mice, Polyunsaturated Alkamides, Molecular Medicine, Animals, General Medicine, Arachidonic Acids, Settore BIO/10, Biochemistry, Endocannabinoids
Abstract

Anandamide or N-arachidonoylethanolamine (AEA) is a signaling lipid that modulates neurotransmitter release via activation of the type 1 cannabinoid receptor (CB1R) in the brain. Termination of anandamide signaling is thought to be mediated via a facilitated cellular reuptake process that utilizes a purported transporter protein. Recently, WOBE437 has been reported as a novel, natural product-based inhibitor of AEA reuptake that is active in cellular and in vivo models. To profile its target interaction landscape, we synthesized pac-WOBE, a photoactivatable probe derivative of WOBE437, and performed chemical proteomics in mouse neuroblastoma Neuro-2a cells. Surprisingly WOBE437, unlike the widely used selective inhibitor of AEA uptake OMDM-1, was found to increase AEA uptake in Neuro-2a cells. In line with this, WOBE437 reduced the cellular levels of AEA and related N-acylethanolamines (NAEs). Using pac-WOBE, we identified saccharopine dehydrogenase-like oxidoreductase (SCCPDH), vesicle amine transport 1 (VAT1), and ferrochelatase (FECH) as WOBE437-interacting proteins in Neuro-2a cells. Further genetic studies indicated that SCCPDH and VAT1 were not responsible for the WOBE437-induced reduction in NAE levels. Regardless of the precise mechanism of action of WOB437 in AEA transport, we have identified SSCPHD, VAT1, and FECH as unprecedented off-targets of this molecule which should be taken into account when interpreting its cellular and in vivo effects.

Published
2022

26. Oral anticoagulants in the oldest old with recent stroke and atrial fibrillation

Author

Polymeris, A. A., Macha, K., Paciaroni, M., Wilson, D., Koga, M., Cappellari, M., Schaedelin, S., Zietz, A., Peters, N., Seiffge, D. J., Haupenthal, D., Gassmann, L., De Marchis, G. M., Wang, R., Gensicke, H., Stoll, S., Thilemann, S., Avramiotis, N. S., Bonetti, B., Tsivgoulis, G., Ambler, G., Alberti, A., Yoshimura, S., Brown, M. M., Shiozawa, M., Lip, G. Y. H., Venti, M., Acciarresi, M., Tanaka, K., Mosconi, M. G., Takagi, M., Jager, R. H., Muir, K., Inoue, M., Schwab, S., Bonati, L. H., Lyrer, P. A., Toyoda, K., Caso, V., Werring, D. J., Kallmunzer, B., Engelter, S. T., Traenka, C., Hert, L., Wagner, B., Schaub, F., Meya, L., Fladt, J., Dittrich, T., Fisch, U., Volbers, B., Siedler, G., Bovi, P., Tomelleri, G., Micheletti, N., Zivelonghi, C., Emiliani, A., Parry-Jones, A., Patterson, C., Price, C., Elmarimi, A., Parry, A., Nallasivam, A., Nor, A. M., Esis, B., Bruce, D., Bhaskaran, B., Roffe, C., Cullen, C., Holmes, C., Cohen, D., Hargroves, D., Mangion, D., Chadha, D., Vahidassr, D., Manawadu, D., Giallombardo, E., Warburton, E., Flossman, E., Gunathilagan, G., Proschel, H., Emsley, H., Anwar, I., Burger, I., Okwera, J., Putterill, J., O'Connell, J., Bamford, J., Corrigan, J., Scott, J., Birns, J., Kee, K., Saastamoinen, K., Pasco, K., Dani, K., Sekaran, L., Choy, L., Iveson, L., Mamun, M., Sajid, M., Cooper, M., Burn, M., Smith, M., Power, M., Davis, M., Smyth, N., Veltkamp, R., Sharma, P., Guyler, P., O'Mahony, P., Wilkinson, P., Datta, P., Aghoram, P., Marsh, R., Luder, R., Meenakishundaram, S., Subramonian, S., Leach, S., Ispoglou, S., Andole, S., England, T., Manoj, A., Harrington, F., Rehman, H., Sword, J., Staals, J., Mahawish, K., Harkness, K., Shaw, L., Mccormich, M., Sprigg, N., Mansoor, S., Krishnamurthy, V., Giustozzi, M., Agnelli, G., Becattini, C., D'Amore, C., Cimini, L. A., Bandini, F., Liantinioti, C., Chondrogianni, M., Yaghi, S., Furie, K. L., Tadi, P., Zedde, M., Abdul-Rahim, A. H., Lees, K. R., Carletti, M., Rigatelli, A., Putaala, J., Tomppo, L., Tatlisumak, T., Marcheselli, S., Pezzini, A., Poli, L., Padovani, A., Vannucchi, V., Masotti, L., Sohn, S. -I., Lorenzini, G., Tassi, R., Guideri, F., Acampa, M., Martini, G., Ntaios, G., Athanasakis, G., Makaritsis, K., Karagkiozi, E., Vadikolias, K., Mumoli, N., Galati, F., Sacco, S., Tiseo, C., Corea, F., Ageno, W., Bellesini, M., Colombo, G., Silvestrelli, G., Ciccone, A., Lanari, A., Scoditti, U., Denti, L., Mancuso, M., Maccarrone, M., Ulivi, L., Orlandi, G., Giannini, N., Tassinari, T., De Lodovici, M. L., Rueckert, C., Baldi, A., Toni, D., Letteri, F., Pieroni, A., Giuntini, M., Lotti, E. M., Flomin, Y., Kargiotis, O., Karapanayiotides, T., Monaco, S., Baronello, M. M., Csiba, L., Szabo, L., Chiti, A., Giorli, E., Del Sette, M., Imberti, D., Zabzuni, D., Doronin, B., Volodina, V., Michel, P., Vanacker, P., Barlinn, K., Pallesen, L. -P., Barlinn, J., Deleu, D., Melikyan, G., Ibrahim, F., Akhtar, N., Gourbali, V., Todo, K., Kimura, K., Shibazaki, K., Yagita, Y., Furui, E., Itabashi, R., Terasaki, T., Shiokawa, Y., Hirano, T., Suzuki, R., Kamiyama, K., Nakagawara, J., Takizawa, S., Homma, K., Okuda, S., Okada, Y., Maeda, K., Kameda, T., Kario, K., Nagakane, Y., Hasegawa, Y., Akiyama, H., Shibuya, S., Mochizuki, H., Ito, Y., Nakashima, T., Matsuoka, H., Takamatsu, K., Nishiyama, K., Endo, K., Miyagi, T., Osaki, M., Kobayashi, J., Okata, T., Tanaka, E., Sakamoto, Y., Tokunaga, K., Takizawa, H., Takasugi, J., Matsubara, S., Higashida, K., Matsuki, T., Kinoshita, N., Ide, T., Yoshimoto, T., Ando, D., Fujita, K., Kumamoto, M., Kamimura, T., Kikuno, M., Mizoguchi, T., and Sato, T.

Subjects
Male, medicine.medical_specialty, Vitamin K, medicine.drug_class, 610 Medicine & health, Aged, 80 and over, Atrial Fibrillation, Factor Xa Inhibitors, Female, Humans, Stroke, Continuous variable, Internal medicine, 80 and over, medicine, Aged, Proportional hazards model, business.industry, Anticoagulant, Confounding, Atrial fibrillation, Patient data, medicine.disease, Oldest old, Neurology, Neurology (clinical), 610 Medizin und Gesundheit, business
Abstract

Objective: To investigate the safety and effectiveness of direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA) after recent stroke in patients with atrial fibrillation (AF) aged ≥85 years. Methods: Individual patient data analysis from seven prospective stroke cohorts. We compared DOAC versus VKA treatment among patients with AF and recent stroke (≥85y = 0.65, 95%-CI [0.52, 0.81]) and < 85 years (HR = 0.79, 95%-CI [0.66, 0.95]) in simple (p interaction = 0.129), adjusted (p interaction = 0.094) or weighted (p interaction = 0.512) models. Analyses on recurrent stroke, ICH and death separately were consistent with the primary analysis, as were sensitivity analyses using age dichotomized at 90 years and as a continuous variable. DOAC had a similar net clinical benefit in patients aged ≥85 (+1.73 to +2.66) and < 85 years (+1.90 to +3.36 events/100 patient-years for ICH-weights 1.5 to 3.1). Interpretation: The favorable profile of DOAC over VKA in patients with AF and recent stroke was maintained in the oldest old. ANN NEUROL 2021.

Published
2022
Full Text
View/download PDF

27. Oral Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation

Author

Polymeris, A.A. Macha, K. Paciaroni, M. Wilson, D. Koga, M. Cappellari, M. Schaedelin, S. Zietz, A. Peters, N. Seiffge, D.J. Haupenthal, D. Gassmann, L. De Marchis, G.M. Wang, R. Gensicke, H. Stoll, S. Thilemann, S. Avramiotis, N.S. Bonetti, B. Tsivgoulis, G. Ambler, G. Alberti, A. Yoshimura, S. Brown, M.M. Shiozawa, M. Lip, G.Y.H. Venti, M. Acciarresi, M. Tanaka, K. Mosconi, M.G. Takagi, M. Jäger, R.H. Muir, K. Inoue, M. Schwab, S. Bonati, L.H. Lyrer, P.A. Toyoda, K. Caso, V. Werring, D.J. Kallmünzer, B. Engelter, S.T. Engelter, S.T. Lyrer, P.A. Bonati, L.H. Seiffge, D.J. Traenka, C. Polymeris, A.A. Zietz, A. Peters, N. De Marchis, G.M. Thilemann, S. Avramiotis, N.S. Gensicke, H. Hert, L. Wagner, B. Schaub, F. Meya, L. Fladt, J. Dittrich, T. Fisch, U. Macha, K. Haupenthal, D. Gassmann, L. Wang, R. Stoll, S. Schwab, S. Volbers, B. Siedler, G. Kallmünzer, B. Cappellari, M. Bonetti, B. Bovi, P. Tomelleri, G. Micheletti, N. Zivelonghi, C. Emiliani, A. Parry-Jones, A. Patterson, C. Price, C. Elmarimi, A. Parry, A. Nallasivam, A. Nor, A.M. Esis, B. Bruce, D. Bhaskaran, B. Roffe, C. Cullen, C. Holmes, C. Cohen, D. Hargroves, D. Mangion, D. Chadha, D. Vahidassr, D. Manawadu, D. Giallombardo, E. Warburton, E. Flossman, E. Gunathilagan, G. Proschel, H. Emsley, H. Anwar, I. Burger, I. Okwera, J. Putterill, J. O’Connell, J. Bamford, J. Corrigan, J. Scott, J. Birns, J. Kee, K. Saastamoinen, K. Pasco, K. Dani, K. Sekaran, L. Choy, L. Iveson, L. Mamun, M. Sajid, M. Cooper, M. Burn, M. Smith, M. Power, M. Davis, M. Smyth, N. Veltkamp, R. Sharma, P. Guyler, P. O’Mahony, P. Wilkinson, P. Datta, P. Aghoram, P. Marsh, R. Luder, R. Meenakishundaram, S. Subramonian, S. Leach, S. Ispoglou, S. Andole, S. England, T. Manoj, A. Harrington, F. Rehman, H. Sword, J. Staals, J. Mahawish, K. Harkness, K. Shaw, L. McCormich, M. Sprigg, N. Mansoor, S. Krishnamurthy, V. Giustozzi, M. Acciarresi, M. Agnelli, G. Becattini, C. Alberti, A. D’Amore, C. Cimini, L.A. Bandini, F. Tsivgoulis, G. Liantinioti, C. Chondrogianni, M. Yaghi, S. Furie, K.L. Tadi, P. Zedde, M. Abdul-Rahim, A.H. Lees, K.R. Bovi, P. Carletti, M. Rigatelli, A. Cappellari, M. Putaala, J. Tomppo, L. Tatlisumak, T. Marcheselli, S. Pezzini, A. Poli, L. Padovani, A. Vannucchi, V. Masotti, L. Sohn, S.-I. Lorenzini, G. Tassi, R. Guideri, F. Acampa, M. Martini, G. Ntaios, G. Athanasakis, G. Makaritsis, K. Karagkiozi, E. Vadikolias, K. Mumoli, N. Galati, F. Sacco, S. Tiseo, C. Corea, F. Ageno, W. Bellesini, M. Colombo, G. Silvestrelli, G. Ciccone, A. Lanari, A. Scoditti, U. Denti, L. Mancuso, M. Maccarrone, M. Ulivi, L. Orlandi, G. Giannini, N. Tassinari, T. De Lodovici, M.L. Rueckert, C. Baldi, A. Toni, D. Letteri, F. Pieroni, A. Giuntini, M. Lotti, E.M. Flomin, Y. Kargiotis, O. Karapanayiotides, T. Monaco, S. Baronello, M.M. Csiba, L. Szabó, L. Chiti, A. Giorli, E. Del Sette, M. Imberti, D. Zabzuni, D. Doronin, B. Volodina, V. Michel, P. Vanacker, P. Barlinn, K. Pallesen, L.-P. Barlinn, J. Deleu, D. Melikyan, G. Ibrahim, F. Akhtar, N. Gourbali, V. Todo, K. Kimura, K. Shibazaki, K. Yagita, Y. Furui, E. Itabashi, R. Terasaki, T. Shiokawa, Y. Hirano, T. Suzuki, R. Kamiyama, K. Nakagawara, J. Takizawa, S. Homma, K. Okuda, S. Okada, Y. Maeda, K. Kameda, T. Kario, K. Nagakane, Y. Hasegawa, Y. Akiyama, H. Shibuya, S. Mochizuki, H. Ito, Y. Nakashima, T. Matsuoka, H. Takamatsu, K. Nishiyama, K. Tanaka, K. Endo, K. Miyagi, T. Osaki, M. Kobayashi, J. Okata, T. Tanaka, E. Sakamoto, Y. Tokunaga, K. Takizawa, H. Takasugi, J. Matsubara, S. Higashida, K. Matsuki, T. Kinoshita, N. Shiozawa, M. Ide, T. Yoshimoto, T. Ando, D. Fujita, K. Kumamoto, M. Kamimura, T. Kikuno, M. Mizoguchi, T. Sato, T. NOACISP-LONGTERM, Erlangen Registry, CROMIS-2, RAF, RAF-DOAC, SAMURAI-NVAF Verona Registry Collaborators

Abstract

Objective: To investigate the safety and effectiveness of direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA) after recent stroke in patients with atrial fibrillation (AF) aged ≥85 years. Methods: Individual patient data analysis from seven prospective stroke cohorts. We compared DOAC versus VKA treatment among patients with AF and recent stroke (

Published
2022

37. Biochimica del sangue

Author

Gasperi, V, Catani, M, and Maccarrone, M

Subjects
Settore BIO/10
Published
2021

38. Preface

Author

Maccarrone, M.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results